Loading AI tools
Iranian-American ophthalmologist and retina surgeon known for inventing LASIK eye surgery From Wikipedia, the free encyclopedia
Gholam A. Peyman (born 1 January 1937) is an Iranian American ophthalmologist, retina surgeon, and inventor. He is best known for his invention of LASIK eye surgery,[2] a vision correction procedure designed to allow people to see clearly without glasses. He was awarded the first US patent for the procedure in 1989.
Gholam A. Peyman | |
|---|---|
| |
| Born | Gholam Ali Peyman 1 January 1937[1] |
| Nationality | Iranian American |
| Alma mater | University of Freiburg University of Essen |
| Known for | Inventor of LASIK[2] |
| Awards | National Medal of Technology and Innovation (2012) |
| Scientific career | |
| Fields | Ophthalmology, Engineering |
| Institutions | Professor of Basic Medical Sciences at the University of Arizona, Phoenix & Optical Sciences at University of Arizona Tucson, Arizona Emeritus Professor of Ophthalmology, Tulane University |
Peyman was born in Shiraz, Iran. At the age of 19, he moved to Germany to begin his medical studies. He received his MD at the University of Freiburg in 1962.[citation needed] He completed his internship at St. Johannes Hospital in Duisburg, Germany in 1964 and at Passaic General Hospital in Passaic, New Jersey in 1965.[citation needed] Peyman completed his residency in ophthalmology and a retina fellowship at the University of Essen, Essen Germany, in 1969 and an additional postdoctoral fellowship in retina at the Jules Stein Eye Institute, UCLA School of Medicine in Los Angeles in 1971. Peyman held the position of assistant professor of ophthalmology at the UCLA School of Medicine from 1971 and served as associate professor and then professor of ophthalmology and ocular oncology at the Illinois Eye and Ear Infirmary, University of Illinois at Chicago during 1971–1987.[citation needed]
Peyman held a joint appointment at the School of Medicine and also at the Neuroscience Center of Excellence at the Louisiana State University Medical University Medical Center in New Orleans during 1987–2000. During 1998-2000 Peyman held the Prince Abdul Aziz Bin Ahmed Bin Abdul Aziz Al Saud Chair in Retinal Diseases. During 2000–2006, Peyman served as professor of ophthalmology, ocular oncology and co-director, Vitreo-Retinal Service, Tulane University School of Medicine in New Orleans.[citation needed]
During 2006–2007, he was professor of ophthalmology at the University of Arizona, Tucson, with a cross appointment at University of Arizona College of Optical Sciences. He has been emeritus professor of ophthalmology at Tulane University since 2009.[citation needed]
Peyman is currently professor of basic medical sciences at the University of Arizona College of Medicine – Phoenix & Optical engineering at the University of Arizona in Tucson. Peyman was awarded in 2013 an honoree doctorate degree from the National University of Cordoba in Argentina.[3]
At the Illinois Eye and Ear Infirmary, Peyman, because of his interest in the effects of lasers on tissues in the eye, began evaluating the potential use of a CO2 laser to modify corneal refraction in rabbits. No prior study had existed on this concept. The laser was applied to the surface of the cornea using different patterns. This laser created significant scarring. His conclusions at that time were: 1) one has to wait for the development of an ablative laser and 2) one should not ablate the surface of the cornea but, instead, the ablation should take place under a flap in order to prevent scarring, pain and other undesirable sequelae. Peyman published the first article on this subject in 1980.[4]
In late 1982, he read an article from IBM Laboratories, published in Laser Focus, describing the photo-ablative properties of an excimer laser on organic material. This was very exciting information, but, unfortunately, Peyman did not have access to this laser, which at the time was new and very expensive. By 1985 and beyond, many investigators were interested in ablating the corneal surface. However, because of his previous experience with the CO2 laser, Peyman wanted to avoid surface ablation in order to prevent potential corneal scarring and the pain associated with the removal of the corneal epithelium, necessary to expose the surface of the cornea. Therefore, in July 1985, he applied for a patent that described a method of modifying corneal refractive errors using laser ablation under a corneal flap. This US patent was accepted after two revisions and issued in June, 1989. Peyman performed a number of experimental studies evaluating the effect of various excimer lasers in collaboration with Physics Department of the University of Helsinki, Finland. Since he had purchased an Erb-Yag laser in the U.S., he evaluated the concept using this laser in vivo in rabbit and primate eyes and described the creation of a hinged corneal flap to enable the ablation to be performed on the exposed corneal bed, thus reducing the potential for postoperative scarring and pain.[5]
Always aware of the potential limitations of his invention, Peyman devoted considerable time and effort in subsequent years to ameliorating them. In order to improve the risk/benefit considerations of the LASIK procedure, he invented in 2004 and patented a broad range of ablative and non-ablative inlays to be placed under the surgically created corneal flap (US Patent 6,702,807). These inlays offered many potential advantages over the standard LASIK technique, the most significant of which is that the inlay procedure is reversible.[6]
However, their ablation was not predictable. In October 2009, Peyman invented and applied for a patent on a method of preventing corneal implant rejection, which was approved in 2017 (US Patent 9,681,942). It consisted of forming a Lasik flap in the cornea, raising the flap, inserting a lamellar cornea under the flap so as to overlie the exposed stromal tissue. The inlay is ablated with wavefront guided excimer laser, to correct the refractive errors of the eye, applying a cross linking solution to the inlay and stromal tissue of the cornea, replacing the corneal flap and cross linking the inlay with UV radiation, killing the cellular elements in the inlay and its surrounding cornea, preventing cellular migration in the inlay and its rejection or encapsulation by the host corneal cells. This new procedure is now called “Mesoick” (Meso means Inside, Implant, Crosslinking Keratomileusis (US Patent 9,037,033). This creates an immune privileged cell free space that does not initiate an immune response to an implant. A synthetic, crosslinked organic or polymeric lens can be implanted in the corneal pocket to compensate for the patient's refractive error. The implant can be exchanged as the eye grows or refractive need dictates.[7]
Peyman has been granted 200 US Patents[8] covering a broad range of novel medical devices, intra-ocular drug delivery, surgical techniques, as well as new methods of diagnosis and treatment.
Development of direct intraocular drug delivery and Vitrectomy
Surgical removal of intraocular tumors
This technology enables an ophthalmologist to treat a patient located in another location e.g. another city by a laser system controlled remotely, via the internet, using a sophisticated secure system in a non-contact fashion.
| US Patent 9,931,171 | Laser treatment of an eye structure or a body surface from a remote location |
| US Patent 9,510,974 | Laser coagulation of an eye structure or a body surface from a remote location |
| US Patent 9,037,217 | Laser coagulation of an eye structure or a body surface from a remote location |
| US Patent 8,903,468 | Laser coagulation of an eye structure from a remote location |
| US Patent 8,452,372 | System for laser coagulation of the retina from a remote location |
Development of precision thermotherapy in oncology Therapy of malignant tumors in early-stage along with imaging and immune therapy and precision localized drug delivery:
| US Patent 10,376,600 | Early disease detection and therapy |
| US Patent 10,300,121 | Early cancer detection and enhance immunotherpay |
| US Patent 9,849,092 | Early cancer detection and enhance immunotherapy |
| US Patent 9,393,396 | Method and composition for hyperthermally treating cells |
Tele-laser system and tele- medicine with a novel Dynamic Identity recognition
| US Patent 10,456,209 | Remote laser treatment system with dynamic imaging |
Macular degeneration
Intravitreal slow-release Rock inhibitors alone or in combination with Anti-VEGF
| US Patent 10,272,035 | Ophthalmic drug delivery method |
| US Patent 9,486,357 | Ophthalmic drug delivery system and method |
| US Patent 10,278,920 | Drug delivery implant and a method using the same |
Artificial Retina Stimulation
Quantum dots and Optogenetic for artificial retinal and brain stimulation and gene therapy
Gene therapy with non-viral nanoparticles and CRISPR
Adaptic optic phoropter for automated vision correction and Tunable light field camera in use for VR and AR technology
Among other awards and honors, Peyman has received the National Medal of Technology and Innovation (2012),[18] the Waring Medal of the Journal of Refractive Surgery (2008),[19] and the American Academy of Ophthalmology's Lifetime Achievement Award (2008)[20] He was named a fellow of the National Academy of Inventors in 2013.[21]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.
